You are here: Home » Companies » News
Business Standard

GVK Biosciences to sign one more research deal

BS Reporter  |  Chennai/ Hyderabad 

GVK Biosciences, a Hyderabad-based contract research organisation, will be signing one more collaborative research deal during this financial year, taking the total to five.

“We are focusing on three therapeutic areas that include diabetes, pain and inflammation,” Manni Kantipudi, president of GVK Bio told mediapersons here on Tuesday. He, however, declined to spell out the name of the multinational (MNC) or the deal size.

GVK Bio already has collaborative deals with two MNCs, including the one with Wyeth Pharmaceuticals, for research in drugs for humans and fungicides. It recently signed two more deals, which are yet to be announced, he added.

As the Indian government does not allow the first-in-man studies (Phase-I clinical trials) for drugs discovered outside of India, Kantipudi said GVK Biosciences, along with other players, had made representations to India’s apex drug regulatory body the Drug Controllers General of India (DCGI).

“The DCGI had said that it will not permit first-in-man studies to be conducted in India at least for the next three years. We will do it (Phase-I clinical trials), if the regulator approves it,” said Shoibal Mukherjee, senior vice-president (clinical development), GVK Bio, adding the company was weighing various options to set up a facility for Phase-I clinical trials outside India. “It will, however, take some time,” he said.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, August 05 2009. 00:07 IST
RECOMMENDED FOR YOU
.